Track record · closed signal

Novo Nordisk A/S (NVO) — closed signal from January 22, 2026

Partial Published before the outcome was known, scored automatically when the window closed on April 22, 2026 — -36.3% at the close.

Predicted vs. what happened

NVO price · publication thesis → realized outcomesplit-adjusted

$62.00 – $58.50Entry zone — fair-value band

$61.42Published — price the day we called it

$67.56Target — the price the thesis aimed for

$64.16Peak — highest point inside the window, not a realized return

$39.15Window close — end-of-window price, context only

What happened

Partial

Reached 45% of the predicted growth at its peak, without hitting the target.

At window close

-36.3%

realized, from the publication price to the last close inside the window

Peak gain

+4.5%

peak, from the publication price — not a realized return

S&P 500, same window

+3.5%

SPY over the identical days, dividend-adjusted

Window close

$39.15

last close inside the window, ended April 22, 2026

Peak price

$64.16

peak on January 23, 2026 — not a realized return

Days to target

—

The thesis — published January 22, 2026

Predicted growth

+10%

over the measurement window

Target price

$67.56

the price the thesis aimed for

Entry zone

$62.00 – $58.50

the fair-value band we waited for

Price at publication

$61.42

published January 22, 2026

Confidence

67%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Novo Nordisk has been moving higher recently and new availability of oral Wegovy has kept interest positive. That means short-term demand could stay strong, but the stock has already run up so buying on dips in the entry zone is safer. Key risks: valuation pullbacks, pricing or access headlines, and a crowded trade reversing fast.

Primary drivers

Oral Wegovy listed on a new platform makes it easier for patients to get it
GLP-1 drugs are a big growth area in healthcare demand
As a large company, it may be steadier in volatile markets
Many traders owning the stock can cause quick reversals on bad news

How it played out

NVO: target was not reached

Lyra published NVO at $61.42 on 2026-01-22 with a short-term thesis for 10% growth. The thesis pointed to recent strength, easier oral Wegovy access, broad GLP-1 healthcare demand, large-company steadiness, and the risk that a crowded trade could reverse quickly on bad news.

Inside the window, NVO peaked at $64.16 on 2026-01-23, a 4.5% gain. It stayed below the $67.56 target and never reached it. By 2026-04-22, it ended at $39.15. The thesis only partly played out early, then missed by the end of the window.

What happened during the window

On 2026-02-03, Novo Nordisk released fourth-quarter results early and said 2026 adjusted sales would fall by 5% to 13%. On 2026-02-04, another report said the company expected a sharp revenue decline in 2026 and cited pricing pressure, competition, and patent issues in the company's outlook.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All NVO signals